Show simple item record

dc.contributor.authorSee Hoe, Louise E
dc.contributor.authorBartnikowski, Nicole
dc.contributor.authorWells, Matthew A
dc.contributor.authorSuen, Jacky Y
dc.contributor.authorFraser, John F
dc.date.accessioned2019-08-16T03:24:02Z
dc.date.available2019-08-16T03:24:02Z
dc.date.issued2019
dc.identifier.issn1422-0067
dc.identifier.doi10.3390/ijms20153823
dc.identifier.urihttp://hdl.handle.net/10072/386621
dc.description.abstractCardiovascular disease is the largest contributor to worldwide mortality, and the deleterious impact of heart failure (HF) is projected to grow exponentially in the future. As heart transplantation (HTx) is the only effective treatment for end-stage HF, development of mechanical circulatory support (MCS) technology has unveiled additional therapeutic options for refractory cardiac disease. Unfortunately, despite both MCS and HTx being quintessential treatments for significant cardiac impairment, associated morbidity and mortality remain high. MCS technology continues to evolve, but is associated with numerous disturbances to cardiac function (e.g., oxidative damage, arrhythmias). Following MCS intervention, HTx is frequently the destination option for survival of critically ill cardiac patients. While effective, donor hearts are scarce, thus limiting HTx to few qualifying patients, and HTx remains correlated with substantial post-HTx complications. While MCS and HTx are vital to survival of critically ill cardiac patients, cardioprotective strategies to improve outcomes from these treatments are highly desirable. Accordingly, this review summarizes the current status of MCS and HTx in the clinic, and the associated cardiac complications inherent to these treatments. Furthermore, we detail current research being undertaken to improve cardiac outcomes following MCS/HTx, and important considerations for reducing the significant morbidity and mortality associated with these necessary treatment strategies.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.publisher.placeChina
dc.relation.ispartofpagefrom3823-1
dc.relation.ispartofpageto3823-45
dc.relation.ispartofissue15
dc.relation.ispartofjournalInternational Journal of Molecular Sciences
dc.relation.ispartofvolume20
dc.subject.fieldofresearchOther chemical sciences
dc.subject.fieldofresearchGenetics
dc.subject.fieldofresearchOther biological sciences
dc.subject.fieldofresearchCardiovascular medicine and haematology
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3499
dc.subject.fieldofresearchcode3105
dc.subject.fieldofresearchcode3199
dc.subject.fieldofresearchcode3201
dc.subject.fieldofresearchcode3202
dc.subject.keywordscardioprotection
dc.subject.keywordsheart failure
dc.subject.keywordsheart transplantation
dc.subject.keywordsmechanical circulatory support
dc.subject.keywordscardioprotection
dc.titleHurdles to Cardioprotection in the Critically Ill
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSee Hoe, LE; Bartnikowski, N; Wells, MA; Suen, JY; Fraser, JF, Hurdles to Cardioprotection in the Critically Ill., International Journal of Molecular Sciences, 2019, 20 (15), pp. 3823-1-3823-45
dcterms.dateAccepted2019-08-03
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2019-08-16T03:17:33Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
gro.hasfulltextFull Text
gro.griffith.authorSee Hoe, Louise
gro.griffith.authorWells, Matt A.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record